// App-Quantinova.ai

822P : Phenotypic circulating tumor cell (CTC) classifier of genomic instability (GI) associates with improved overall survival (OS) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving platinum agents in addition to taxanes

Researchers

Presenter

  • H.Scher

Principal Investigators

  • R.P.Graf

  • A.Jendrisak

  • B.McLaughlin

  • E.Barnett

  • N.A.Schreiber

  • J.Lee

  • J.Kelvin

  • Y.Wang

  • M.Landers

  • R.Dittamore

Medical Centers

  • Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

  • Translational Research, Epic Sciences Inc., San Diego, CA, USA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • taxane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved